CPT code 86367 represents a quantitative laboratory assay for counting CD34-positive stem cells in a patient specimen, typically peripheral blood. This measurement guides timing and eligibility for hematopoietic stem cell collection and related therapies, making it clinically important across transplant, oncology, and hematology services nationwide. The code is primarily used by hospital and independent clinical laboratories supporting inpatient and outpatient specimen collection.

Key payers covered in this national discussion include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for CD34 enumeration, common sites of service, and the role of this test in care pathways. The publication summarizes available benchmarks and payment considerations where available, highlights common billing and coding themes, and outlines implications for laboratory operations and clinical workflows. Data not available in the input is noted where specific payer policies, associated taxonomies, and ICD-10 mappings are not provided. The content is intended to inform laboratory managers, billing professionals, and clinician stakeholders about the clinical purpose and billing context of CPT code 86367 at a national level.